The Cavix commercial enterprise begins with the launch of our first proprietary technology: a unique synthetic bone graft for spinal and orthopedic indications in companion animals. This regenerative bioceramic is the result of years of academic research and clinical development by leading biomaterial experts and veterinary surgeons in the Cavix founding team.
Our state-of-the-art synthetic bone graft with novel bone regenerative properties is currently in clinical evaluation prior to commercial launch in Europe and the US. In parallel, our technology platform will continue to expand into complementary veterinary therapies emerging both from our own research as well as from licensing and acquisition.
“As surgeons, we need to join forces with the biomaterial research community. Any new technology that can improve success, minimize trauma and shorten recovery times can be vital to the future of veterinary care.”
- Odd Höglund, Cavix founder, Associate Professor in Veterinary Science at Swedish University of Agricultural Sciences)